AIM IMMUNOTECH INC

AIMNYSE AMERICAN

🏆 #5463 by market capEarnings Nov 16US Equity

$0.17▼ $0.01 (−5.52%)

Live

🔔

Track AIM

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 5.5%

7d▼ 17.6%

14d▼ 19.5%

30d▼ 32.4%

ytd▼ 84.4%

1y▼ 93.5%

🏦Market Cap

$588,813

Small Cap

📈Revenue Growth (YoY)

-48.2%

Declining

📊Gross Margin

-125.3%

Thin

💵FCF Margin

-7536.8%

Thin

⚖️P/S Ratio

6.6x

Fair

Otter Score

Fair

Trading Snapshot

Day Range: $0.17 – $0.18
52-Week Range: $0.18 – $2.79
Volume: $1.95B
Avg Volume: $1.57B
Shares Outstanding: 3.4M
Next Earnings: Oct 26, 2026

Fundamentals Snapshot

Annual Revenue: $88,000
Last Q Revenue: $26,000
P/E Ratio: -0.0
P/S Ratio: 6.6x
EPS (TTM): $-0.83
Dividend Yield: 0.00%
Dilution (1yr): +96.1%

Why Investors Own AIM

✓High-growth profile — revenue up +13.2% YoY with expanding US Equity exposure.
✓Healthy economics — 39% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AIM IMMUNOTECH INC

AIM

Financial Trends

Revenue

$88K▼ −48.2% YoY

Gross Margin

-284.1%▼ −447.4% YoY

Operating Income

−$11M▼ −46.8% YoY

Free Cash Flow

−$11M▼ −24.0% YoY

Shares Outstanding

3.1M▲ +96.1% YoY

Net Cash

−$4M▼ −$3M YoY

StockOtter · stockotter.space

About AIM IMMUNOTECH INC

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.

🦦